Re-evaluating Biopsy for Recurrent Glioblastoma: A Position Statement by the Christopher Davidson Forum Investigators

Edjah K. Nduom, Melanie Hayden Gephart, Milan G. Chheda, Mario L. Suva, Nduka Amankulor, James D. Battiste, Jian L. Campian, Ralph G. Dacey, Sunit Das, Peter E. Fecci, Constantinos G. Hadjipanayis, Kimberly B. Hoang, Ali Jalali, Daniel Orringer, Akash J. Patel, DImitris Placantonakis, Analiz Rodriguez, Isaac Yang, Jennifer S. Yu, Greg J. ZipfelGavin P. Dunn, Eric C. Leuthardt, Albert H. Kim

Research output: Contribution to journalArticlepeer-review

Abstract

Patients with glioblastoma (GBM) need bold new approaches to their treatment, yet progress has been hindered by a relative inability to dynamically track treatment response, mechanisms of resistance, evolution of targetable mutations, and changes in mutational burden.We arewriting on behalf of amultidisciplinary group of academic neuro-oncology professionals who met at the collaborative Christopher Davidson Forum at Washington University in St Louis in the fall of 2019. We propose a dramatic but necessary change to the routine management of patients with GBM to advance the field: to routinely biopsy recurrent GBM at the time of presumed recurrence. Data derived from these samples will identify true recurrence vs treatment effect, avoid treatments with little chance of success, enable clinical trial access, and aid in the scientific advancement of our understanding of GBM.

Original languageEnglish
Pages (from-to)129-132
Number of pages4
JournalNeurosurgery
Volume89
Issue number1
DOIs
StatePublished - Jul 1 2021

Keywords

  • Clinical trials
  • Glioblastoma
  • Personalized medicine
  • Pseudoprogression
  • Recurrent glioblastoma
  • Stereotactic biopsy

Fingerprint

Dive into the research topics of 'Re-evaluating Biopsy for Recurrent Glioblastoma: A Position Statement by the Christopher Davidson Forum Investigators'. Together they form a unique fingerprint.

Cite this